FBIO News and Press, Fortress Biotech Inc. From 04/24/24

MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...

2024-04-11 12:24:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one. Viking Therapeutics (NASDAQ: VKTX ) is the...

2024-03-28 16:57:58 ET More on Fortress Biotech Journey Medical announces U.S. FDA acceptance of NDA for its rosacea treatment Seeking Alpha’s Quant Rating on Fortress Biotech Historical earnings data for Fortress Biotech Financial information for Fort...

Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in ad...

2024-03-28 11:09:29 ET More on Mustang Bio Seeking Alpha’s Quant Rating on Mustang Bio Historical earnings data for Mustang Bio Financial information for Mustang Bio Read the full article on Seeking Alpha For further details see: Mustang Bi...

Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024 MB-106 data in B-cell non-Hodgkin lymphoma (NHL) provide a strong founda...

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights....

Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings in 2023, ahead of initial guidance of $...

2024-03-19 07:17:00 ET Update Mar. 19, 2023, 07.17 AM EST: Adds details about Fortress Biotech More on Journey Medical Journey Medical submits NDA for DFD-29 for rosacea Journey Medical secures credit facility for up to $20M Seeking Alpha’s Quant Ratin...